A trial aiming to investigate the safety and efficacy of a new drug in patients with primary immune thrombocytopenia previously treated with other standard of care medications

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Hellenic Society Of Hematology

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Hemic and Lymphatic Diseases [C15]

Trial duration

30 Sep 2025 → ongoing

Decision date (initial)

2025-02-11

Transition trial

No

Low-intervention

No

Rare-disease indication

Yes

Vulnerable population

Yes

Funding sources

GlaxoSmithKline Research and Development Limited

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Safety

To evaluate the clinical efficacy of treatment with belantamab mafodotin.

Secondary objectives 3

1. To evaluate the safety of treatment with belantamab mafodotin.
2. To further evaluate the clinical efficacy of treatment with belantamab mafodotin.
3. To evaluate vision-related functioning measured by the Vision Related Anamnestic Tool as documented by the investigator.

Conditions and MedDRA coding

Primary Immune Thrombocytopenia

Study design 3 periods

Regulatory references

Plan to share IPD

No

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 9

1. Participants must be 18 years or older.
2. Primary ITP with platelet cell count of less than 30x10^9/L.
3. Prior first-line therapy with corticosteroids.
4. Prior second-line therapy with TPO-RA and/or rituximab and failure to achieve or retain response.
5. Adequate organ system function as defined by the below laboratory assessments. Hematologic a. Absolute neutrophil count ≥1.5x10^9/L; granulocyte colony stimulating factor use within the past 14 days is NOT permitted. b. Hemoglobin ≥8.0 g/dL; transfusions within the past 14 days are NOT permitted. Erythropoietin use is allowed. Hepatic a. Total bilirubin ≤1.5xULN (isolated bilirubin ≥1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). b. Alanine aminotransferase ≤ 2.5xULN. Renal a. Estimate glomerular filtration rate ≥30 mL/min/1.73 m2 calculated using the Modification of Diet in Renal Disease formula.
6. Female participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: • Is not a woman of childbearing potential (WOCBP) defined as follows: a. ≥45 years of age and has not had menses for >1 year with no other cause. b. Any participant who have been amenorrhoeic for >1year but <2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation. c. Post-hysterectomy, post-bilateral oophorectomy, or post-bilateral tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure. OR • Is a WOCBP using a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency during the intervention period and for 4 months after the last dose of belantamab mafodotin and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of trial intervention. • WOCBP must have a negative highly sensitive serum pregnancy test within 10 to 14 days prior to the start of treatment and the second pregnancy test must be performed within 24 hours prior to the start of treatment and agree to use a highly effective method of contraception during the trial and for 4 months after the last dose of belantamab mafodotin. Additional requirements for pregnancy testing during and after trial intervention are provided in Section 10. Trial Procedures and Visit Schedule. The investigator is responsible for a review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a nearly undetected pregnancy.
7. Male participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to the following during the intervention period and until 6 months after the last dose of belantamab mafodotin, whichever is longer, to allow for clearance of any altered sperm. • Refrain from donating sperm PLUS either: • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, OR • Must agree to use contraception/barrier as detailed below: Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of <1% per year as when having sexual intercourse with a woman of childbearing potential (including pregnant females).
8. Eastern Cooperative Oncology Group Performance Status ≤2.
9. Participants must be able to understand the trial procedures and agree to participate in the trial by providing written informed consent.

Exclusion criteria 18

1. Secondary ITP including: i. Drug induced ITP. ii. ITP associated with any autoimmune disorders (e.g., systemic lupus erythematosus, and rheumatoid arthritis). iii. ITP associated with chronic infection including but not limited to (e.g., human immunodeficiency virus, hepatitis C virus, and helicobacter pylori). iv. ITP associated with malignancy (e.g., chronic lymphocytic leukemia or large granular T-lymphocyte lymphocytic leukemia).
2. Chronic liver disease. Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice. NOTE: Stable non-cirrhotic chronic liver disease (including Gilbert’s syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria.
3. To be seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]) at screening or within 3 months prior to first dose of trial treatment. NOTE 1: Participants with resolved infection (i.e., participants who are positive for antibodies to hepatitis B core antigen [anti-HBc] or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR). Those who are PCR positive will be excluded. NOTE 2: presence of anti-HBs indicating previous vaccination will not constitute an exclusion criterion.
4. To be seropositive for hepatitis C at screening or within 3 months prior to first dose of trial treatment. NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Hepatitis RNA testing is optional and participants with negative hepatitis C antibody test do not require to also undergo hepatitis C RNA testing.
5. Known HIV infection, unless the participant meets all of the following criteria: a. Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load <400 copies/mL b. CD4+ T-cell (CD4+) counts ≥350 cells/uL c. No history of AIDS-defining opportunistic infections within the last 12 months NOTE: consideration must be given to ART and prophylactic antimicrobials that may have a drug:drug interaction and/or overlapping toxicities with belantamab mafodotin or other combination products as relevant.
6. Active infection requiring treatment.
7. Active renal condition (infection, requirement for dialysis, or any other significant condition that could affect participant’s safety).
8. Any serious and/or unstable pre-existing medical or psychiatric disorder, or other conditions (including laboratory abnormalities) that could interfere with participant’s safety, obtaining informed consent, or compliance to the trial procedures.
9. Participant must not have received a live or live-attenuated vaccine within 30 days prior to first dose of belantamab mafodotin.
10. Current corneal epithelial disease except for mild punctate keratopathy. NOTE: Participants with mild punctate keratopathy are allowed. Mild (Grade 1) punctuate keratopathy is characterized by the appearance of only a few, if any, microcyst-like epithelial changes, as identified in the slit-lamp examination, with a low density (non-confluent), and predominantly (≥80%) located in the periphery of the cornea.
11. Known intolerance or immediate or delayed hypersensitivity reaction or idiosyncratic reaction to: drugs chemically related to belantamab mafodotin, or dexamethasone or any of the components of the trial treatment; or infused protein products, sucrose, histidine, and polysorbate 80.
12. Use of an investigational drug within 14 days or 5 halflives (whichever is shorter)preceding the first dose of trial drug.
13. Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of trial drug. Please note,monoclonal antibodies for serious conditions unrelated to ITP, such as COVID, may be permitted but need to be discussed with the Sponsor
14. Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, skin changes) or active plasma cell leukemia at the time of screening
15. Evidence of active mucosal or internal bleeding.
16. Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain
17. Major surgery within 4 weeks before the first dose of trial drug. NOTE 1: participants must be clinically stable following a major surgery to be entered in the trial. NOTE 2: major surgery shall be defined based on the Investigator’s judgment according to the extent and complexity of the procedure, its pathophysiological consequences and consecutive clinical outcomes.
18. Evidence of cardiovascular risk including any of the following: i. Evidence of current clinically significant untreated arrhythmias, including clinically significant electrocardiogram (ECG) abnormalities, second degree (Mobitz Type II), or third degree atrioventricular block. ii. Screening 12-lead ECG showing a baseline QT interval >470 msec iii. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening. iv. Class III or IV heart failure as defined by the New York Heart Association functional classification system (Appendix 3 – New York Heart association (NYHA) Classification v. Uncontrolled hypertension

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Complete response rate (CRR)/Partial response rate (PRR) at 6 months of treatment.

Secondary endpoints 9

1. Patients with treatment-emergent adverse events (AEs) and serious AEs.
2. Overall response rate at 2, 6 and 12 months.
3. Complete response rate at 12 months.
4. Time to response (TTR)
5. Duration of response (DoR).
6. ORR.
7. Number of participants with abnormal ocular findings (on ophthalmic exam).
8. Belantamab mafodotin dose holds.
9. Number and proportion of participants with changes from baseline in ocular symptoms and related impacts as measured by the Vision Related Anamnestic Tool

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Hellenic Society Of Hematology

Sponsor organisation

Hellenic Society Of Hematology

Address

Kifissias Leoforos 27

City

Athens

Postcode

115 23

Country

Greece

Scientific contact point

Organisation

Hellenic Society Of Hematology

Contact name

Prof. Evangelos Terpos

Public contact point

Organisation

Hellenic Society Of Hematology

Contact name

Prof. Georgios Vasilopoulos

Third parties 7

Locations

1 EU/EEA country · 2 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 7 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

2 submissions — initial application plus substantial / non-substantial modifications